Glancy Prongay & Murray LLP Reminds Investors of the Deadline in the Class Action Lawsuit Against Amarin Corporation plc (AMRN)
LOS ANGELES--(BUSINESS WIRE)--Mar 5, 2019--Glancy Prongay & Murray LLP (“GPM”) reminds investors of the April 23, 2019 deadline to file a lead plaintiff motion in the class action filed on behalf of investors that purchased Amarin Corporation plc (“Amarin” or the “Company”) (NASDAQ: AMRN ) securities between September 24, 2018 and November 9, 2018, inclusive (the “Class Period”). Amarin investors have until April 23, 2019 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here to participate.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to email@example.com, or visit our website at www.glancylaw.com.
On November 12, 2018, an article was published on Seeking Alpha regarding Amarin’s “recent revelations of positive topline results” from its REDUCE-IT trial for Vascepa, its sole product. The article raised the possibility that “the placebo group received an active agent that in effect was an anti-statin,” and that the REDUCE-IT trial results may have consequently exaggerated the efficacy of Vascepa. On this news, Amarin’s American depositary receipt price fell $4.44, or 22%, to close at $15.38 on November 13, 2018, thereby injuring investors.
The complaint filed in this class action alleges that Defendants made materially false and misleading statements and/or failed to disclose that: (1) the top-line results Amarin touted about its REDUCE-IT trial for Vascepa were not as positive as the company represented; (2) the placebo given to patients in the control arm of REDUCE-IT may have increased the incidence of cardiovascular events in those patients; (3) as a result, Amarin’s public statements were materially false and misleading at all relevant times.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares of Amarin, you may move the Court no later than April 23, 2019 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to firstname.lastname@example.org, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190305006054/en/
CONTACT: Glancy Prongay and Murray LLP, Los Angeles
Lesley Portnoy, 310-201-9150 or 888-773-9224
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL
SOURCE: Glancy Prongay & Murray LLP
Copyright Business Wire 2019.
PUB: 03/05/2019 07:40 PM/DISC: 03/05/2019 07:40 PM